
    
      This is a multi-centre, multinational, prospective, non-interventional study in females with
      a diagnosis of moderate to severe uterine fibroids, and for whom a treatment with Esmya in a
      long term manner is planned, and in subjects who were previously exposed to UPA in the long
      term Phase III studies. It is planned to enrol approximately 1,500 patients. Consecutive,
      eligible, patients will be invited to enrol from approximately 100-150 European Union (EU)
      clinical practice sites in approximately 15 countries. Patients will be followed for an
      observation period of 60 months (5 years) from treatment start. Investigators are to manage
      and treat patients according to their standard medical practice.
    
  